Jeffrey A. Lieberman
YOU?
Author Swipe
View article: Ensuring generalizability and clinical utility in mental health care applications: Robust artificial intelligence‐based treatment predictions in diverse psychosis populations
Ensuring generalizability and clinical utility in mental health care applications: Robust artificial intelligence‐based treatment predictions in diverse psychosis populations Open
Aim Artificial Intelligence (AI)‐based prediction models of treatment response promise to revolutionize psychiatric care by enabling personalized treatment, but very few have been thoroughly tested in different samples or compared to curre…
View article: A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical Trial
A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical Trial Open
Despite decades of research, cognitive impairment remains a critical untreated symptom for many patients with schizophrenia. One way to accelerate the development of pro-cognitive therapies for schizophrenia is to evaluate compounds using …
View article: Analysis of schizophrenia‐associated genetic markers in the HLA region as risk factors for tardive dyskinesia
Analysis of schizophrenia‐associated genetic markers in the HLA region as risk factors for tardive dyskinesia Open
Objectives The pathology of Tardive Dyskinesia (TD) has yet to be fully understood, but there have been proposed hypotheses for the cause of this condition. Our team previously reported a possible association of TD with the Complement Comp…
View article: An analysis of motivating factors in 1,725 worldwide cases of mass murder between 1900-2019
An analysis of motivating factors in 1,725 worldwide cases of mass murder between 1900-2019 Open
Mass murder, particularly mass shootings, constitutes a major, growing public health concern. Specific motivations for these acts are not well understood, often overattributed to severe mental illness. Identifying diverse factors motivatin…
View article: Hippocampal Glutamate and Positive Symptom Severity in Clinical High Risk for Psychosis
Hippocampal Glutamate and Positive Symptom Severity in Clinical High Risk for Psychosis Open
This study examines the association between increased hippocampal glutamate and higher total positive symptom severity in converters to psychosis.
View article: High-impact rare genetic variants in severe schizophrenia
High-impact rare genetic variants in severe schizophrenia Open
Significance In this study, we found that selecting individuals with extremely severe forms of schizophrenia led to a significantly improved ability to detect disease-associated rare variants. The high prevalence of rare variant risk facto…
View article: Perinatal neurosteroid levels influence GABAergic interneuron localization in adult rat prefrontal cortex
Perinatal neurosteroid levels influence GABAergic interneuron localization in adult rat prefrontal cortex Open
Neurosteroids are a class of steroids synthesized de novo in the brain, several of which are potent modulators of GABAA receptor function. In developing brain GABAA receptor, stimulation plays a trophic role. Cortical levels of the GABAerg…
View article: Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease Open
BACKGROUND Second-generation (atypical) antipsychotic drugs are widely used to treat psychosis, aggression, and agitation in patients with Alzheimer's disease, but their benefits are uncertain and concerns about safety have emerged. We ass…
View article: RanBP1, a velocardiofacial/DiGeorge syndrome candidate gene, is expressed at sites of mesenchymal/epithelial induction
RanBP1, a velocardiofacial/DiGeorge syndrome candidate gene, is expressed at sites of mesenchymal/epithelial induction Open
RanBP1, a velocardiofacial syndrome/DiGeorge syndrome candidate gene, is expressed in the frontonasal processes, branchial arches, aortic arches, and limb buds. At these sites, RanBP1 apparently coincides with neural crest-derived mesenchy…
View article: Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder
Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder Open
Glutamate (Glu) and gamma-aminobutyric acid (GABA) are implicated in the pathophysiology of major depressive disorder (MDD). GABA levels or GABAergic interneuron numbers are generally low in MDD, potentially disinhibiting Glu release. It i…
View article: Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia Open
BACKGROUND The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-…
View article: Effects of risperidone on auditory event-related potentials in schizophrenia
Effects of risperidone on auditory event-related potentials in schizophrenia Open
Schizophrenia is associated with cognitive deficits for which treatments remain elusive. The effects of risperidone (an antipsychotic differing in some of its pharmacological properties from typical agents) on cognitive deficits have not b…
View article: Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia
Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia Open
The neurosteroid pregnenolone and its sulfated derivative enhance learning and memory in rodents. Pregnenolone sulfate also positively modulates NMDA receptors and could thus ameliorate hypothesized NMDA receptor hypofunction in schizophre…
View article: Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia Open
In a 5-week trial, xanomeline-trospium resulted in a greater decrease in the PANSS total score than placebo but was associated with cholinergic and anticholinergic adverse events. Larger and longer trials are required to determine the effi…
View article: Results of phase 3 of the CATIE schizophrenia trial
Results of phase 3 of the CATIE schizophrenia trial Open
Objective—The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study examined the comparative effectiveness of antipsychotic treatments for individuals with chronic schizophrenia. Patients who had discontinued antipsycho…
View article: Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia
Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia Open
According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of th…
View article: Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia
Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia Open
We compared the response to antipsychotic treatment between patients with and without tardive dyskinesia (TD) and examined the course of TD.
View article: Aggression and Quantitative MRI Measures of Caudate in Patients With Chronic Schizophrenia or Schizoaffective Disorder
Aggression and Quantitative MRI Measures of Caudate in Patients With Chronic Schizophrenia or Schizoaffective Disorder Open
Caudate dysfunction is implicated in schizophrenia. However, little is known about the relationship between aggression and caudate volumes. Forty-nine patients received magnetic resonance imaging scanning in a double-blind treatment study …
View article: Two-stage empirical likelihood for longitudinal neuroimaging data
Two-stage empirical likelihood for longitudinal neuroimaging data Open
Longitudinal imaging studies are essential to understanding the neural development of neuropsychiatric disorders, substance use disorders, and the normal brain. The main objective of this paper is to develop a two-stage adjusted exponentia…
View article: Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1 Open
The metabolic syndrome (MS) is associated with increased risk for diabetes mellitus and coronary heart disease, and is highly prevalent among schizophrenia patients. Given concerns over antipsychotic metabolic effects, this analysis explor…
View article: Association of RGS2 and RGS5 variants with schizophrenia symptom severity
Association of RGS2 and RGS5 variants with schizophrenia symptom severity Open
Several lines of evidence indicate that Regulator of G Protein Signaling 4 (RGS4) contributes to schizophrenia vulnerability. RGS4 is one of a family of molecules that modulate signaling via G-protein coupled receptors. Five genes encoding…
View article: Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression
Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression Open
Although the etiology of schizophrenia remains unknown, diverse neuropathological evidence suggests a disorder of synaptic connectivity. Apoptosis is a form of cell death that helps determine synaptic circuitry during neurodevelopment and …
View article: Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study Open
Persons with schizophrenia die earlier than the general population, in large part due to cardiovascular disease. The study objective was to examine effects of different antipsychotic treatments on estimates of 10 year coronary heart diseas…
View article: Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type
Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type Open
Caudate and hippocampal volume differences in patients with schizophrenia are associated with disease and antipsychotic treatment, but local shape alterations have not been thoroughly examined.
View article: Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder
Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder Open
The relationship between orbitofrontal cortex (OFC) volumes and functional domains in treatment-resistant patients with schizophrenia or schizoaffective disorder is poorly undestood. OFC dysfunction is implicated in several of the behavior…